Related Experiment Video

Updated: Jun 18, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Genomics of heart failure

Raghava S Velagaleti1, Christopher J O'Donnell

  • 1The NHLBI's Framingham Heart Study, 73 Mt. Wayte Avenue, Suite 2, Framingham, MA 01702, USA.

Heart Failure Clinics
|December 1, 2009
PubMed

Insights

Genetic factors influencing heart failure (HF) are being explored using advanced genomics. Genome-wide association studies and sequencing offer new insights into cardiovascular disease susceptibility.

Area of Science:

  • Genomics and Cardiovascular Disease Research

Background:

  • Cardiovascular disease (CVD) is a primary cause of mortality globally.
  • Heart failure (HF), a common CVD, presents significant morbidity and mortality rates.
  • The heritability of common HF forms is modest, with prior genetic studies focusing on rare familial cases or candidate genes.

Purpose of the Study:

  • To review the advancements in genomic research for understanding heart failure.
  • To highlight the potential of new technologies like genome-wide sequencing and "omics" in CVD research.

Main Methods:

  • Review of current literature on genomics and heart failure.
  • Discussion of genome-wide association studies (GWAS) enabled by the Human Genome Project and HapMap.
  • Exploration of emerging "omics" technologies.

Main Results:

  • Large-scale genome-wide association studies are now feasible for investigating HF genetic susceptibility.
  • Genome-wide sequencing and other "omics" provide powerful tools for comprehensive genetic analysis.
  • These advancements move beyond traditional candidate gene approaches.

Conclusions:

  • Genomic approaches, including GWAS and sequencing, are revolutionizing the study of heart failure.
  • Understanding the genetic basis of HF is crucial for addressing its high mortality and morbidity.
  • Future research will likely leverage comprehensive "omics" data for personalized cardiovascular medicine.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...